Ustekinumab in enteropathic arthritis

Ulusoy B. Ö., Erden A., Güven S. C., Armaǧan B., Yürekli Ö. T., Özin Y. Ö., ...More

Immunotherapy, vol.15, no.8, pp.583-592, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 8
  • Publication Date: 2023
  • Doi Number: 10.2217/imt-2022-0197
  • Journal Name: Immunotherapy
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.583-592
  • Keywords: Crohn's disease, enteropathic arthritis, inflammatory bowel disease, spondyloarthropathy, ulcerative colitis, ustekinumab
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

Objective: The aim of this study was to evaluate the efficacy of ustekinumab in the treatment of enteropathic arthritis. Materials & methods: A systematic literature search was performed in the Pubmed database of publications between January 2010 and October 2021. Demographic characteristics, comorbidities, inflammatory bowel disease and enteropathic arthritis symptoms, other extraintestinal findings, medical treatments and clinical and laboratory findings for all cases were recorded. Results: A total of 11 patients were included. While clinical and laboratory remission was achieved in terms of inflammatory bowel disease in all patients and enteropathic arthritis in nine patients after ustekinumab treatment, other extraintestinal findings for all patients completely regressed after treatment. Conclusion: Ustekinumab may be an appropriate treatment option for this patient group, considering both pathogenesis and successful treatment responses.